You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Pipeline Information

Development Programs – Solid Tumor

Drug

Indication

Phase 1

Phase 2

Phase 3


BGB-3245 (BRAF inhibitor)

Advanced solid tumors with B-RAF mutations

Lifirafenib (RAF inhibitor) + PD-0325901 (MEK inhibitor)

Advanced solid tumors

Pamiparib (PARP 1/2 inhibitor)

2L/3L maintenance platinum-sensitive OC

1L maintenance platinum-sensitive GC

BRCA+ and HER2– BC

Advanced OC and TNBC

Pamiparib + Temozolomide

Advanced solid tumors

Tislelizumab (anti-PD-1)

2L advanced ESCC

1L HCC

2L/3L NSCLC

Previously treated unresectable HCC

Previously treated advanced MSI-high or dMMR solid tumors

Tislelizumab + BGB-A425 (anti-TIM-3)

Advanced solid tumors

Tislelizumab + BGB-A445 (anti-OX40)

Advanced solid tumors

Tislelizumab + Ociperlimab (anti-TIGIT)

1L PD-L1 high advanced NSCLC

2L PD-L1+ advanced ESCC

2L+ cervical cancer

Advanced solid tumors

Tislelizumab + Ociperlimab + BAT1706

1L HCC

Tislelizumab + Ociperlimab + Chemotherapy

1L NSCLC

Tislelizumab + Ociperlimab + Concurrent Chemoradiotherapy

Previously untreated, stage III unresectable NSCLC

Previously untreated LS-SCLC

Tislelizumab + BGB-10188 (PI3Kδ inhibitor)

Advanced solid tumors

Tislelizumab + BGB-15025 (HPK1 inhibitor)

Advanced solid tumors

Tislelizumab + Chemoradiotherapy

Localized ESCC

Tislelizumab + Chemotherapy/ Chemoradiotherapy

Resectable ESCC

Tislelizumab + Chemotherapy

1L advanced ESCC

1L GC/GEJC

Resectable stage II or IIIA NSCLC

1L advanced nasopharyngeal cancer

1L squamous NSCLC

1L non-squamous NSCLC

1L advanced UBC

1L ES-SCLC

Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy

1L/2L GC/GEJC

Tislelizumab + Fruquintinib (VEGFR inhibitor)

Advanced GC/GEJC, CRC, and NSCLC

Advanced triple negative BC

Tislelizumab + Lenvatinib

1L HCC

Advanced solid tumors

Tislelizumab + Sitravatinib (multikinase inhibitor)

Advanced NSCLC after anti-PD-(L)1 therapy

Advanced GC/GEJC/HCC

Advanced solid tumors

Tislelizumab + Surufatinib (VEGFR, FGFR, CSF-1R inhibitor)

Advanced solid tumors

Zanidatamab (anti-HER2 bispecific antibody)

2L+ HER2+ BTC

Zanidatamab + Chemotherapy +/- Tislelizumab

1L HER2+ BC and 1L HER2+ GC/GEJC

Australia
Australia, China
Australia, New Zealand
Australia, New Zealand, US
Australia, S.Korea, US
Australia, US
China
China, Korea
China, S. Korea, Taiwan
China, Taiwan
China, Taiwan, Thailand
S. Korea, Taiwan
S. Korea, US
United States
Worldwide

BC, breast cancer; BRAF, B-Raf proto-oncogene; BRCA+, breast cancer susceptibility gene-positive; BTC, biliary tract cancer; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC; extensive-stage small cell lung cancer; GBM, glioblastoma multiforme; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocelluar carcinoma; HER2-, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; OC, ovarian cancer; R/R, recurrent/refractory; SCLC, small lung cell cancer; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer.

Development Programs – Hematology

Drug

Indication

Phase 1

Phase 2

Phase 3


Tislelizumab (anti-PD-1)

R/R cHL

R/R cHL

BGB-10188 +/- Tislelizumab

B-cell malignancies

BGB-10188 (PI3Kδ inhibitor) +/- Zanubrutinib (BTK inhibitor)

B-cell lymphoid malignancies

BGB-11417 (Bcl-2 inhibitor) monotherapy

Mature B-cell malignancies

Zandelisib (PI3Kδ inhibitor) +/- Zanubrutinib or Rituximab*

CLL/SLL and B-cell NHL

Zanubrutinib

R/R CLL/SLL

1L and R/R WM

R/R MZL

Previously treated B-cell lymphoid malignancies

B-cell lymphoid malignancies

Zanubrutinib + Lenalidomide +/- Rituximab

R/R DLBCL

Zanubrutinib + Obinutuzumab

R/R FL

Zanubrutinib + Rituximab

1L MCL

Zanubrutinib +/- Venetoclax

1L CLL/SLL

Australia
China
Japan
Switzerland, US
United States
Worldwide

* In collaboration with MEI Pharma
This combination is being studied in the third cohort of NCT03336333

B-cell NHL, B-cell non-Hodgkins lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphotic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B cell-like; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NK, natural killer; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; WM, Waldenstrӧm macroglobulinemia.

Videos

PARPI Mechanism of Action

Anti-PD-1 Mechanism of Action

BTKI Mechanism of Action